JP2011530524A5 - - Google Patents

Download PDF

Info

Publication number
JP2011530524A5
JP2011530524A5 JP2011522218A JP2011522218A JP2011530524A5 JP 2011530524 A5 JP2011530524 A5 JP 2011530524A5 JP 2011522218 A JP2011522218 A JP 2011522218A JP 2011522218 A JP2011522218 A JP 2011522218A JP 2011530524 A5 JP2011530524 A5 JP 2011530524A5
Authority
JP
Japan
Prior art keywords
substance
stabilizer
temperature
pharmaceutical substance
liquid formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011522218A
Other languages
English (en)
Japanese (ja)
Other versions
JP5785077B2 (ja
JP2011530524A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/052852 external-priority patent/WO2010017296A1/en
Publication of JP2011530524A publication Critical patent/JP2011530524A/ja
Publication of JP2011530524A5 publication Critical patent/JP2011530524A5/ja
Application granted granted Critical
Publication of JP5785077B2 publication Critical patent/JP5785077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011522218A 2008-08-05 2009-08-05 崩壊温度より高温での凍結乾燥 Active JP5785077B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8642608P 2008-08-05 2008-08-05
US61/086,426 2008-08-05
PCT/US2009/052852 WO2010017296A1 (en) 2008-08-05 2009-08-05 Lyophilization above collapse

Publications (3)

Publication Number Publication Date
JP2011530524A JP2011530524A (ja) 2011-12-22
JP2011530524A5 true JP2011530524A5 (enExample) 2012-09-13
JP5785077B2 JP5785077B2 (ja) 2015-09-24

Family

ID=41401614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011522218A Active JP5785077B2 (ja) 2008-08-05 2009-08-05 崩壊温度より高温での凍結乾燥

Country Status (6)

Country Link
US (1) US9884019B2 (enExample)
EP (2) EP2323629B1 (enExample)
JP (1) JP5785077B2 (enExample)
CA (1) CA2729972C (enExample)
ES (2) ES2755029T3 (enExample)
WO (1) WO2010017296A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007305255A1 (en) * 2006-10-03 2008-04-10 Wyeth Lyophilization methods and apparatuses
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
US8058237B2 (en) 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
CN102026619A (zh) * 2008-04-14 2011-04-20 先进科技及再生医学有限责任公司 液体缓冲的gdf-5制剂
CA2729972C (en) 2008-08-05 2018-11-20 Wyeth Llc Lyophilization above collapse
CN105189559B (zh) 2013-03-15 2021-07-13 塔科达有限责任公司 抗体制剂及其用途
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
SG10201913735SA (en) 2014-03-24 2020-03-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3323410A1 (en) * 2016-11-22 2018-05-23 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. Pharmaceutical parenteral formulation containing carglumic acid
CN107543373B (zh) * 2017-09-06 2019-04-26 华派生物工程集团有限公司 一种活疫苗的冷冻干燥方法
KR20210021299A (ko) 2018-05-10 2021-02-25 리제너론 파아마슈티컬스, 인크. 고농도 vegf 수용체 융합 단백질 함유 제제
CN109369821B (zh) * 2018-11-28 2021-12-14 四川恒通动保生物科技有限公司 一种黄芪多糖的高效提取制备方法
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
US11525629B2 (en) * 2020-02-04 2022-12-13 Regeneron Pharmaceuticals, Inc. Target residual moisture content for lyophilized drug product

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298261A (en) 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
BR9507909A (pt) * 1994-06-03 1997-08-12 Procter & Gamble Formas de dosagem de rápida dissolução
RU2111426C1 (ru) 1995-11-03 1998-05-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Способ лиофильной сушки биопрепарата
ES2253877T3 (es) 1998-03-03 2006-06-01 SHIONOGI & CO., LTD. Composiciones farmaceuticas que contienen el inhibidor de fosfolipasa((3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-1h-indol-4-il)oxi)acetato de sodio.
EP2193809B1 (en) * 1999-02-22 2015-04-08 University of Connecticut Albumin-free factor VIII formulations
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
CA2569276C (en) 2004-06-02 2018-01-23 Victor Bronshtein Preservation by vaporization
US7632491B2 (en) * 2004-08-12 2009-12-15 Schering Corporation Stable pegylated interferon formulation
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
WO2006081320A2 (en) 2005-01-27 2006-08-03 Human Genome Sciences, Inc. Pharmaceutical formulation
CN101378782A (zh) * 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
CA2726837A1 (en) 2008-06-26 2009-12-30 Wyeth Llc Lyophilization cycle robustness strategy
CA2729972C (en) 2008-08-05 2018-11-20 Wyeth Llc Lyophilization above collapse

Similar Documents

Publication Publication Date Title
JP2011530524A5 (enExample)
Gupta et al. Platforms, advances, and technical challenges in virus-like particles-based vaccines
Pardeshi et al. Process development and quality attributes for the freeze-drying process in pharmaceuticals, biopharmaceuticals and nanomedicine delivery: a state-of-the-art review
CN113755523B (zh) 重组前融合状态新冠刺突蛋白的制备方法
Amorij et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying
JP2022166110A (ja) アデノウイルスコートタンパク質由来送達賦形剤
JP6881813B2 (ja) 核酸ワクチン
CN102202688B (zh) 稳定、干燥的轮状病毒疫苗、其组合物和制备其的方法
JP5785077B2 (ja) 崩壊温度より高温での凍結乾燥
JP6053969B2 (ja) ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
CN101443038B (zh) 尼古丁-载体疫苗制剂
Thérien et al. A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling
CN103041383A (zh) 一种活疫苗的耐热冻干保护剂、活疫苗冻干粉及其制备方法
CA2851176C (en) Stabilisation of polypeptides
JP2015521628A (ja) ウイルス様粒子の精製
RU2011127913A (ru) Составы, содержащие антитела
KR20240046787A (ko) 지질 나노-에멀젼 입자에 흡착된 mRNA의 동결건조 제제
JP2018533597A (ja) 第viii因子を含有する凍結乾燥ペレットの製造方法
JP4875497B2 (ja) バクテリオファージナノ粒子を含む方法および組成物
CN102223788A (zh) 保存混合物及其用途
US20160000901A1 (en) Compositions and Methods for the Production of Virus-Like Particles
Zeltins Protein complexes and virus-like particle technology
EP3127550A1 (en) Stabilizing composition for dry formulation of virus
KR100563942B1 (ko) 분자 물질의 모듈 운반 시스템 및 그의 제조 방법 및 용도
WO2012070968A1 (ru) Способ молекулярного дизайна и синтеза лечебных и профилактических лекарст- венных препаратов